The winner of the Rice Business Plan Competition walked away with over $700,000 in prizes. Courtesy of Rice University

On Saturday, over 20 organizations were prepared to write checks to entrepreneurs competing in the Rice Business Plan Competition, but the largest and richest student business plan competition doled out almost double what it initially intended to award.

Earlier this year, Rice University announced the 42 teams that would be competing for $1.5 million in prizes, but ended up giving out a record $2.9 million. While a few organizations announced they had trouble picking a single company and named two recipients, Houston-based GOOSE Society surprised everyone with almost $1 million in unexpected prizes.

"It shows the diversity in expertise and interest of our investors, and how much the quality of the deals grown at RBPC," says Samantha Lewis, director at GOOSE.

GOOSE, which is a network of investors, originally intended to provide the grand prize — a $350,000 check to the company with the top score from the judges. The 2019 grand prize winner was Vita Inclinata Technologies, a company from the Mitchell Hamline School of Law that created a technology to advance helicopter safety. On top of that, GOOSE investors tacked on five more prizes.

  • $300,000 to Resonado, a more efficient speaker design company, from the University of Notre Dame
  • $200,000 to Rhaeos, a medical device company that has a wearable sensor for neurosurgical patients, from the Northwestern University
  • $200,000 to spotLESS Materials, a company that created a repellant coating material, from Penn State University
  • $125,000 to CataLight, a more sustainable water filtration system company, from the University of Waterloo
  • $100,000 to BrewBike, a campus bike delivery concept, from Northwestern University and the University of Chicago

GOOSE has surprised the crowd before at past RBPC awards banquets, Lewis says, but that's usually been one or two extra prizes. This is the first year the organization has committed this much — and there's potential for these companies to receive even more.

The group now begins is true due diligence process, Lewis says, and depending on what they find, they could invest more. The 2017 winner, Pennsylvania-based Forest Devices Inc., was awarded GOOSE's $300,000 grand prize, but the company eventually received a $2 million investment instead.

Two Houston-based student teams competed in the program, but neither were named even semifinalists. Curenav from University of Houston didn't receive any prize money, but Rice's LilySpec received the $25,000 Pearland Economic Development Spirit of Entrepreneurship Prize as well as the $1,000 Mercury Fund prize and the $1,000 Orrick Awards Banquet Company Showcase Prize.

The 19th annual contest named seven finalists according to the judges' top scores — all receiving over $100,000 in prizes each.

  • First place: Vita Inclinata Technologies (won a total value of nearly $700,000)
  • Second place: Resonado (won more than $300,000 )
  • Third place: spotLESS Materials (won more than $360,000)
  • Fourth place: Rhaeos (won more than $450,000)
  • Fifth place: Zilper Trenchless, which developed a way to install pipes under streets with minimum effect on the surface, from the Massachusetts Institute of Technology (won more than $435,000)
  • Sixth place: BrewBike (won more than $100,000)
  • Seventh place: CataLight (won more than $140,000)
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.